Clinical Trials
The Society supports its members and other clinicians in the field by promoting various research activities. SMFM does not conduct or endorse the studies or trials below.
If you are interested in posting, please review our clinical trials and studies process guidelines for more information. SMFM charges an administrative fee to post and distribute these studies and clinical trials.
Peripartum Cardiomyopathy Network posted July 23, 2024
The Peripartum Cardiomyopathy Network (PCN) is a network of physicians, nurse practitioners, physician assistants, and nurses at clinical sites across the United States and Canada dedicated to both clinical care and investigation of peripartum cardiomyopathy (PPCM) and heart failure after pregnancy. PPCM is a rare complication of pregnancy, which occurs in 1 of every 2000 live births in the United States. It presents in women late in pregnancy or the first several months postpartum. While most affected women will recover cardiac function over the first year, a large subset of women with PPCM do not recover completely and are left with chronic dilated cardiomyopathy. Peripartum cardiomyopathy remains a major cause of maternal morbidity and mortality.
The rare nature of this disorder has limited the practical experience of most clinicians and has represented a challenge for clinical investigation. For this reason, the PCN was formed in 2009 and currently includes more than 50 clinical sites across the United States and Canada. We aim to provide access to clinicians experienced in managing this disorder for women with PPCM and their physicians. The PCN also hopes to facilitate clinical investigations to further understand the pathogenesis of this disorder, evaluate new therapies, and improve clinical outcomes for women with PPCM.
RISE: Recurrent pregnancy loss Investigational StudiEs posted July 23, 2024
Yale University is leading a groundbreaking study, partnering with 10 other universities, to use whole genome sequencing to uncover the genetic causes of recurrent pregnancy loss (RPL). We aim to identify mutations linked to pregnancy loss and provide answers for couples facing this challenge by testing miscarriage tissue samples and parental DNA.
Participants will have the opportunity to:
- Discover if they have genetic mutations in known RPL-associated genes and receive findings in other genes that may be relevant to future health.
- Contribute to vital research advancing reproductive health.
Eligibility
- Two or more pregnancy losses
- Current loss before 20 weeks with normal karyotype
- No known cause of RPL